Life Sciences & MOBs Sustain Demand Amidst Broader CRE Headwinds
By Majid Radaei, RadCRE · · Market Updates
Despite broader CRE turbulence, life sciences and medical office buildings continue to attract significant investment, with Q4 2025 seeing $6.8 billion in transactions, per CBRE.
Resilience in Healthcare Real Estate: Life Sciences and MOBs Defy CRE Trends
The commercial real estate landscape has been marked by volatility and shifting investor sentiment over the past twelve months. However, two sectors – life sciences and medical office buildings (MOBs) – have persistently demonstrated remarkable resilience, drawing significant capital and maintaining strong fundamentals. This specialized segment continues to benefit from an aging population, advancements in healthcare technology, and robust R&D funding.
Investment Activity Remains Robust in Life Sciences
Investment into the life sciences sector, encompassing lab space, biomanufacturing facilities, and R&D campuses, saw a notable resurgence in late 2025 and early 2026. According to CBRE Research, total investment volume in life sciences properties reached approximately $6.8 billion in Q4 2025, a substantial increase from year-ago figures, signaling renewed investor confidence. Major players like Blackstone and Brookfield have continued to deploy capital strategically. For instance, in Q3 2025, BioMed Realty (a Blackstone portfolio company) expanded its presence in the Cambridge, MA market, acquiring additional R&D lab space in the Kendall Square cluster for an undisclosed sum, further solidifying its dominance in key innovation hubs. Furthermore, venture capital funding for biotech and pharmaceutical companies, a crucial driver of life sciences real estate demand, rebounded to over $10 billion in Q4 2025, according to the National Venture Capital Association (NVCA), ensuring a healthy pipeline for future growth.
Medical Office Buildings: A Stable, Needs-Based Asset Class
Medical Office Buildings (MOBs), characterized by their long-term leases, strong tenant retention, and diversified tenant base, continue to be viewed as a defensive asset class. Average cap rates for MOBs remained compressed compared to other asset classes, typically trading in the 5.5% to 6.5% range in Q1 2026 for core assets, largely consistent with pre-2023 levels for high-quality properties. This stability contrasts sharply with the cap rate expansion experienced in traditional office and retail sectors. Recent notable transactions include Physicians Realty Trust's (now linked with Healthpeak Properties) continued strategic acquisitions in key growth markets. For example, in Q4 2025, a 120,000 square foot MOB portfolio anchored by a major health system in Dallas was reportedly acquired for over $75 million, reflecting investor appetite for well-located, institutional-grade assets. Demand drivers such as the increasing utilization of outpatient services and value-based care models are expected to sustain this trajectory.
RadCRE Perspective
"The persistent strength in life sciences and medical office is not merely a flight to quality; it's a fundamental recognition of underlying demographic and technological shifts," says Majid Radaei, Founder of RAD Commercial Realty. "While some sectors grapple with structural changes, healthcare real estate is underpinned by inelastic demand. We're advising clients to look beyond the top-tier markets like Cambridge and Boston, which remain fiercely competitive with cap rates often sub-5%. Secondary markets with strong academic and hospital anchors, like San Diego's Sorrento Valley, Raleigh-Durham, or even emerging clusters in Texas—where we're seeing MOB cap rates in the 6.0%-6.75% range for high-quality assets—offer compelling risk-adjusted returns. These are not speculative plays; these are essential assets with robust rent growth potential. For our clients looking at financing, lenders are increasingly comfortable with healthcare-anchored assets, offering more favorable terms than for general office, with senior debt in the SOFR + 250-350 bps range for well-leased, modern MOBs. We also see opportunities for preferred equity at 10-14% for value-add life science conversions in undersupplied markets, where development risk is mitigated by strong pre-leasing commitments."
Outlook: Continued Growth and Strategic Investment
Looking ahead, both life sciences and MOB sectors are poised for continued growth. The confluence of demographic tailwinds, significant private and public investment in biotechnology, and the ongoing modernization of healthcare delivery systems ensures sustained demand. Investors are expected to maintain their focus on specialized developers and operators with proven expertise in these complex asset classes. RadCRE remains active in sourcing and structuring investments in this space, leveraging our deep market insights and robust financial modeling capabilities to identify opportunities for our institutional and private clients.
Tags: life sciences real estate, medical office building investment, healthcare real estate, CRE investment, commercial real estate financing
Sources: CBRE Research, National Venture Capital Association (NVCA), CoStar, GlobeSt, Commercial Observer